Read our news

HTL’s new corporate social responsibility strategy will focus on accelerating the company’s commitment to its environment, local ecosystem and employees. HTL’s engagements have been awarded an Ecovadis gold medal in 2023 and are certified by ISO 14001:2015.

HTL Biotechnology’s presence and contributions at CPHI Japan 2023 demonstrated its dedication to advancing pharmaceutical innovation.

As part of the development of HTL innovation and R&D projects, HTL was the proud gold sponsor of the SFB and silver sponsor of the Termis Americas this year.

Two very interesting congresses promoting Tissue Engineering, Regenerative Medicine and Biomaterials.

March 14, 2023

January 26, 2023

HTL accelerates its development strategy with the appointment of François Fournier as Chief Executive Officer (CEO).

HTL announces its incubator’s equity investment in GelMEDIX, an early-stage biotech aiming at revolutionizing ocular and regenerative therapies.

HTL announces Montagu as new investor alongside its historical shareholders, Naxicap and Téthys Invest.

HTL launches a new, cutting-edge bioproduction unit for pharmaceutical-grade biopolymers.

BMG Pharma and HTL sign a development agreement to manufacture BMG’s new biopolymer based on the Hyaluromimethic® Technology

Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion’s Exclusive Botulinum API Manufacturer.

HTL Biotechnology and Terasaki Institute for Biomedical Innovation announce Memorandum of Understanding for research in translational biomaterials.